2.要約四半期連結財務諸表及び主な注記
(1) 要約四半期連結財政状態計算書
| | (単位:百万円) |
| 前連結会計年度 (2025年3月31日) | 当第3四半期連結会計期間 (2025年12月31日) |
資産 | | |
流動資産 | | |
現金及び現金同等物 | 134,933 | 144,314 |
営業債権及びその他の債権 | 65,047 | 75,199 |
その他の金融資産 | 31,820 | 39,944 |
その他の流動資産 | 11,626 | 13,092 |
流動資産合計 | 243,425 | 272,550 |
| | |
非流動資産 | | |
有形固定資産 | 48,609 | 53,625 |
のれん | 111,635 | 125,839 |
無形資産 | 94,884 | 104,362 |
持分法で会計処理されている投資 | 49,945 | 52,487 |
公正価値で測定する金融資産 | 15,120 | 15,654 |
その他の金融資産 | 3,442 | 4,922 |
繰延税金資産 | 7,774 | 8,190 |
その他の非流動資産 | 6,907 | 6,725 |
非流動資産合計 | 338,316 | 371,803 |
資産合計 | 581,741 | 644,353 |
| | (単位:百万円) |
| 前連結会計年度 (2025年3月31日) | 当第3四半期連結会計期間 (2025年12月31日) |
負債及び資本 | | |
負債 | | |
流動負債 | | |
営業債務及びその他の債務 | 49,941 | 55,900 |
借入金 | 3,078 | 3,802 |
未払法人所得税 | 9,017 | 8,973 |
ポイント引当金 | 2,220 | 2,681 |
その他の金融負債 | 5,073 | 9,290 |
その他の流動負債 | 12,786 | 13,537 |
流動負債合計 | 82,114 | 94,183 |
| | |
非流動負債 | | |
借入金 | 21,342 | 29,999 |
その他の金融負債 | 24,618 | 22,296 |
繰延税金負債 | 35,118 | 37,847 |
その他の非流動負債 | 5,751 | 5,830 |
非流動負債合計 | 86,829 | 95,973 |
負債合計 | 168,942 | 190,155 |
| | |
資本 | | |
資本金 | 29,351 | 29,420 |
資本剰余金 | 28,753 | 29,846 |
自己株式 | △37 | △3,692 |
その他の資本の構成要素 | 30,521 | 43,859 |
利益剰余金 | 289,848 | 317,340 |
親会社の所有者に帰属する持分合計 | 378,436 | 416,773 |
非支配持分 | 34,363 | 37,425 |
資本合計 | 412,799 | 454,198 |
負債及び資本合計 | 581,741 | 644,353 |
E0542524130エムスリー株式会社M3, Inc.四半期第3号参考様式 [IFRS](連結)IFRStrueCTE2025-04-012025-12-31Q32026-03-312024-04-012024-12-312025-03-311falsefalsefalse241302025-04-012025-12-31tse-qcediffr-24130:OtherEmergingBusinessMember241302025-04-012025-12-31jpcrp_cor:ReconcilingItemsMember241302024-04-012024-12-31jpcrp_cor:ReportableSegmentsMember241302024-04-012024-12-31tse-qcediffr-24130:MedicalPlatformReportableSegmentMember241302024-04-012024-12-31tse-qcediffr-24130:EvidenceSolutionReportableSegmentMember241302024-04-012024-12-31tse-qcediffr-24130:CareerSolutionReportableSegmentMember241302024-04-012024-12-31tse-qcediffr-24130:SiteSolutionReportableSegmentMember241302024-04-012024-12-31tse-qcediffr-24130:OverseasReportableSegmentMember241302024-04-012024-12-31tse-qcediffr-24130:OtherEmergingBusinessMember241302024-04-012024-12-31jpcrp_cor:ReconcilingItemsMember241302024-04-012024-12-31tse-qcediffr-24130:PatientSolutionReportableSegmentMember241302025-04-012025-12-31tse-qcediffr-24130:PatientSolutionReportableSegmentMember241302024-04-012024-12-31jpigp_cor:RetainedEarningsIFRSMember241302024-04-012024-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember241302024-04-012024-12-31jpigp_cor:TreasurySharesIFRSMember241302024-04-012024-12-31jpigp_cor:CapitalSurplusIFRSMember241302024-04-012024-12-31jpigp_cor:ShareCapitalIFRSMember241302024-03-31jpigp_cor:NonControllingInterestsIFRSMember241302024-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember241302024-03-31jpigp_cor:RetainedEarningsIFRSMember241302024-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember241302024-03-31jpigp_cor:TreasurySharesIFRSMember241302024-03-31jpigp_cor:CapitalSurplusIFRSMember241302024-03-31jpigp_cor:ShareCapitalIFRSMember241302024-03-31241302025-04-012025-12-31jpcrp_cor:ReportableSegmentsMember241302025-04-012025-12-31tse-qcediffr-24130:MedicalPlatformReportableSegmentMember241302025-04-012025-12-31tse-qcediffr-24130:EvidenceSolutionReportableSegmentMember241302025-04-012025-12-31tse-qcediffr-24130:CareerSolutionReportableSegmentMember241302025-04-012025-12-31tse-qcediffr-24130:SiteSolutionReportableSegmentMember241302025-04-012025-12-31tse-qcediffr-24130:OverseasReportableSegmentMember241302025-12-31jpigp_cor:NonControllingInterestsIFRSMember241302026-02-04241302025-12-31241302025-04-012025-12-31241302024-12-31241302024-04-012024-12-31241302025-03-31241302025-04-012025-12-31jpigp_cor:CapitalSurplusIFRSMember241302025-04-012025-12-31jpigp_cor:ShareCapitalIFRSMember241302025-03-31jpigp_cor:NonControllingInterestsIFRSMember241302025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember241302025-03-31jpigp_cor:RetainedEarningsIFRSMember241302025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember241302025-03-31jpigp_cor:TreasurySharesIFRSMember241302025-03-31jpigp_cor:CapitalSurplusIFRSMember241302025-03-31jpigp_cor:ShareCapitalIFRSMember241302024-12-31jpigp_cor:NonControllingInterestsIFRSMember241302024-12-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember241302024-12-31jpigp_cor:RetainedEarningsIFRSMember241302024-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember241302024-12-31jpigp_cor:TreasurySharesIFRSMember241302024-12-31jpigp_cor:CapitalSurplusIFRSMember241302025-04-012025-12-31jpigp_cor:TreasurySharesIFRSMember241302024-12-31jpigp_cor:ShareCapitalIFRSMember241302024-04-012024-12-31jpigp_cor:NonControllingInterestsIFRSMember241302024-04-012024-12-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember241302025-12-31jpigp_cor:RetainedEarningsIFRSMember241302025-12-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember241302025-12-31jpigp_cor:OtherComponentsOfEquityIFRSMember241302025-12-31jpigp_cor:TreasurySharesIFRSMember241302025-12-31jpigp_cor:CapitalSurplusIFRSMember241302025-12-31jpigp_cor:ShareCapitalIFRSMember241302025-04-012025-12-31jpigp_cor:NonControllingInterestsIFRSMember241302025-04-012025-12-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember241302025-04-012025-12-31jpigp_cor:RetainedEarningsIFRSMember241302025-04-012025-12-31jpigp_cor:OtherComponentsOfEquityIFRSMemberxbrli:pureiso4217:JPYiso4217:JPYxbrli:shares